Kiniksa Pharmaceuticals International, plc
KNSA
$76.75
-$1.08-1.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 13.69% | 6.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.69% | 6.01% | |||
| Cost of Revenue | 15.84% | 5.93% | |||
| Gross Profit | 11.93% | 6.06% | |||
| SG&A Expenses | 4.44% | 7.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.98% | 1.45% | |||
| Operating Income | -7.08% | 48.05% | |||
| Income Before Tax | -4.70% | 40.45% | |||
| Income Tax Expenses | -43.37% | 11.23% | |||
| Earnings from Continuing Operations | 12.57% | 59.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.57% | 59.11% | |||
| EBIT | -7.08% | 48.05% | |||
| EBITDA | -6.96% | 46.95% | |||
| EPS Basic | 11.01% | 58.00% | |||
| Normalized Basic EPS | -5.99% | 39.45% | |||
| EPS Diluted | 11.11% | 49.25% | |||
| Normalized Diluted EPS | -5.85% | 39.04% | |||
| Average Basic Shares Outstanding | 1.39% | 0.72% | |||
| Average Diluted Shares Outstanding | 1.20% | 1.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||